Real-world use of fidaxomicin in a large UK tertiary hospital: how effective is it for treating recurrent disease?

[1]  K. Carroll,et al.  Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  B. Guery,et al.  Fidaxomicin for treatment of Clostridium difficile infection in clinical practice: a prospective cohort study in a French University Hospital , 2017, Infection.

[3]  M. Salavert,et al.  The efficacy of fidaxomicin in the treatment of Clostridium difficile infection in a real-world clinical setting: a Spanish multi-centre retrospective cohort , 2017, European Journal of Clinical Microbiology & Infectious Diseases.

[4]  D. Nayar,et al.  The impact of the introduction of fidaxomicin on the management of Clostridium difficile infection in seven NHS secondary care hospitals in England: a series of local service evaluations , 2015, European Journal of Clinical Microbiology & Infectious Diseases.

[5]  K. Bauer,et al.  An Antimicrobial Stewardship Program's Real‐World Experience with Fidaxomicin for Treatment of Clostridium difficile Infection: A Case Series , 2014, Pharmacotherapy.

[6]  D. Gerding,et al.  Novel Fidaxomicin Treatment Regimens for Patients With Multiple Clostridium difficile Infection Recurrences That Are Refractory to Standard Therapies , 2014, Open forum infectious diseases.

[7]  D. Gerding,et al.  Fidaxomicin "chaser" regimen following vancomycin for patients with multiple Clostridium difficile recurrences. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  Derrick W. Crook,et al.  Treatment of First Recurrence of Clostridium difficile Infection: Fidaxomicin Versus Vancomycin , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  D. Crook,et al.  Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. , 2012, The Lancet. Infectious diseases.

[10]  Pamela Sears,et al.  Fidaxomicin versus vancomycin for Clostridium difficile infection. , 2011, The New England journal of medicine.